Sunday July 22, 2018

Viral hepatitis Caused 1.34 mn Deaths Globally: Study

Viral hepatitis was found to be amongst the top ten leading global killers

0
//
28
Viral hepatitis
World Health Organization poster for Hepatitis Campaign. VOA
Republish
Reprint

London, Sep 16, 2017: Viral hepatitis with 1.34 million deaths globally has surpassed all chronic infectious diseases including HIV/AIDS, malaria and tuberculosis, according to a study by Global Burden of Disease.

The study reveals that in 2016, the total deaths caused by viral hepatitis, including liver cancer, acute cases, cirrhosis, hepatitis A, E, B, C and D account for 1.34 million globally, exceeding tuberculosis (1.2 million), HIV/AIDS (1 million) and malaria (719,000).

These staggering death rates occurred despite recent advances in hepatitis C medications that can cure most infections within three months and the availability of highly-effective vaccinations for hepatitis B.

“It’s outrageous, but not surprising, that the Global Burden of Disease Report found that deaths related to viral hepatitis have surpassed HIV, TB and malaria” said Charles Gore, President of the World Hepatitis Alliance — a not-for profit organisation based in London.

“This is largely due to a historic lack of political prioritisation coupled with an absent global funding mechanism,” Gore added, in the paper published in the journal the Lancet.

Further, viral hepatitis was found to be amongst the top ten leading global killers which include heart disease, road accidents, Alzheimer’s disease, amongst others.

Also Read: WHO Calls for stepped up action to Eliminate Hepatitis B and C by 2030 

If this trend has to be reversed, immediate action must be taken at both a regional and national level, said the report, while suggesting measures such as scaling up testing and diagnosis.

Viral hepatitis is a highly contagious liver infection caused by the hepatitis A virus and only 5 per cent of people living with the disease are aware of their conditions there are only few noticeable symptoms.

As a result, many people are either misdiagnosed or do not come forward for testing, increasing the chance of infecting others and missing the opportunity to access life-saving treatment.

Reducing hepatitis related deaths by 65 per cent by 2030 is a key component of the World Health Organization’s Global Hepatitis Strategy.

The strategy, which was adopted by 194 governments, sets out a list of key targets, which, if achieved, will eliminate viral hepatitis by 2030. (IANS)

 

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

FDA Approves Drug to Stop Some Malaria Relapses

Worldwide, malaria infects more than 200 million people a year and kills about half a million, most of them children in Africa

0
FDA
FILE - The GlaxoSmithKline offices in London. On Friday, the U.S. Food and Drug Administration approved GlaxoSmithKline’s Krintafel, a simpler, one-dose treatment, to prevent relapses of a type of malaria. (VOA)

U.S. regulators Friday approved a simpler, one-dose treatment to prevent relapses of malaria.

Standard treatment now takes two weeks and studies show many patients don’t finish taking every dose.

Malaria is caused by parasites that are spread to people through mosquito bites. Anti-malarial drugs can cure the initial infection, but parasites can get into the liver, hide in a dormant form and cause recurrences months or years later. A second drug is used to stop relapses.

The new drug, GlaxoSmithKline’s Krintafel, only targets the kind of malaria that mainly occurs in South America and Southeast Asia. Most malaria cases and deaths are in Africa, and they involve another species.

In testing, one dose of Krintafel worked about the same as two weeks of the standard treatment, preventing relapses in about three-quarters of patients in six months, the company said.

Malaria is caused by parasites that are spread to people through mosquito bites.
Malaria is caused by parasites that are spread to people through mosquito bites. (VOA)

The Food and Drug Administration approved the drug for patients 16 and older, according to GlaxoSmithKline. The company said it’s the first new treatment in six decades for preventing relapses.

GlaxoSmithKline plans to apply soon for approval in Brazil, then other countries where the malaria type is common. It says it will sell the pills at low cost in poor countries.

Millions infected worldwide

Worldwide, malaria infects more than 200 million people a year and kills about half a million, most of them children in Africa. It causes fever, headache, chills and other flulike symptoms. The malaria type Krintafel targets causes about 8.5 million infections annually.

Also Read: Trial Wipes out More Than 80 per cent of Disease-Spreading Mosquitoes

The British drugmaker, working with the World Health Organization, is also developing what could be the world’s first malaria vaccine, but early testing indicates it’s not very effective. Prevention now focuses on using insecticides and bed nets. (VOA)